Altimmune, Inc.(ALT), a developer of novel peptide-based therapeutics for liver and metabolic diseases, said on Monday that its Chief Executive Officer, Vipin Garg, will step down with effect from January 1, 2026.
Subsequently, the company's Chairman, Jerry Durso, will assume the role of CEO in addition to his current responsibility as Chairman.
Durso was appointed to Altimmune's Board in February and was named Chairman of the Board in August.
Earlier, Durso had served as the CEO of Intercept Pharmaceuticals Inc. (ICPT), a company focused on liver diseases. Prior to his role at Intercept, Durso spent over two decades at Sanofi SA (SNY, SAN.PA, SNYNF).
ALT was down by 4.75% at $5.01 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.